Last Update: August 2026
Herpes simplex virus (HSV) is able to remain hidden inside nerve cells for life. New research is helping scientists better understand this latent stage, while also revealing why accurately measuring the amount of hidden virus remains one of the biggest challenges in herpes research.
HSV-1 and HSV-2 are common viral infections. After the initial infection, HSV can travel through sensory nerves and establish a lifelong latent infection in nerve cells. The virus can later reactivate, sometimes causing noticeable symptoms and sometimes occurring without obvious signs.
According to the World Health Organization, an estimated 3.8 billion people under age 50 were living with HSV-1 in 2020, while approximately 520 million people aged 15–49 were living with HSV-2. Most HSV infections are asymptomatic or unrecognized.
For researchers, an important question is no longer simply whether HSV is present. Scientists increasingly want to understand where latent HSV remains, how much viral material is present, what keeps it inactive, and what causes it to reactivate.
What Is Latent Herpes?
Latency is a stage of HSV infection in which the virus remains inside nerve cells without continuously producing infectious virus.
After infection at the skin or mucosal surface, HSV can enter sensory nerve endings and travel to nerve ganglia. There, the virus establishes a lifelong latent infection. WHO describes HSV as a virus that lives inside nerve cells and can alternate between inactive and active states.
When HSV reactivates, newly produced virus can travel back toward the skin or mucosal surface. This may result in an outbreak, although reactivation and viral shedding can also occur without obvious symptoms.
This ability to remain hidden is one reason herpes has proven so difficult to cure.
Read more: Exploring HSV-1 Effects on Brain and Mental Health: What Current Research Says
Why Is Latent HSV Difficult to Measure?
One major problem is the location of the latent infection.
HSV latency occurs primarily in sensory neurons within peripheral nerve ganglia. These structures are located deep inside the body and cannot simply be sampled during a routine clinical appointment.
A swab from the genital area or mouth can help detect active viral shedding. Blood testing can provide evidence of HSV antibodies in appropriate circumstances. However, these tests do not tell researchers the total amount of latent HSV stored throughout a person’s nervous system.
This distinction is extremely important.
A person may have HSV antibodies without knowing how much latent virus is present. Similarly, a negative sample from a particular body site does not demonstrate that latent HSV has been eliminated from the nervous system.
There is currently no routine clinical test that measures an individual’s complete latent HSV reservoir.
New Human Neuron Models Are Changing HSV Research
One of the most interesting developments in recent herpes research is the use of human neurons created from induced pluripotent stem cells.
In a 2025 study published in mBio, researchers developed a system for producing human sensory neurons from induced pluripotent stem cells and establishing HSV-1 latency in those cells.
The researchers reported characteristics associated with latent infection, including an absence of infectious virus, reduced lytic gene expression, latency-associated transcript expression, viral heterochromatin, and the ability to reactivate the latent virus under experimental conditions.
The researchers described the model as a scalable way to investigate HSV latency and reactivation in human sensory neurons.
This is significant because much of the historical research into HSV latency has depended on animal models. Human neuronal systems could provide another way to investigate how HSV behaves in cells that more closely represent human biology.
However, it is important not to confuse a laboratory model with a clinical test. The study provides researchers with a useful experimental system; it does not create a test that can measure latent HSV in individual patients.
Scientists Are Studying Viral Proteins Involved in Latency
Researchers are also examining the specific viral proteins that help HSV maintain its relationship with infected neurons.
A 2025 study investigated the HSV-1 protein ICP34.5 in human induced-pluripotent-stem-cell-derived neurons and mouse neurons. The researchers found that ICP34.5 had an important role in maintaining HSV-1 latency in their human neuron model.
The findings also highlighted differences between human and mouse neuronal systems.
This is important because HSV biology can vary between experimental models. A mechanism observed in one type of neuron may not behave identically in another.
Understanding these differences could help scientists identify biological targets that are more relevant to human HSV infection.
It does not mean that ICP34.5 is currently an approved treatment target or that an HSV cure is available.
Single-Cell Technology Offers New Possibilities
Another developing area is single-cell analysis.
Traditional laboratory techniques often analyze populations of cells together. Single-cell technologies allow scientists to examine individual cells and investigate differences in gene activity and viral signals.
This could eventually help researchers understand why some infected neurons remain latent while others reactivate.
It may also help scientists determine whether different neurons contain different amounts or forms of viral material.
But sophisticated technology does not automatically guarantee an accurate result.
Researchers must determine whether a detected viral signal genuinely comes from an infected cell or results from contamination or technical problems during sample collection and analysis.
That makes validation particularly important when scientists study latent HSV.
What Are Scientists Trying to Measure?
Researchers are interested in several different measurements.
They may want to determine whether viral DNA is present, whether particular viral genes are active, whether viral DNA is associated with specific forms of chromatin, whether infectious virus can be recovered, and whether the latent virus can be experimentally reactivated.
These measurements answer different questions.
For example, detecting HSV DNA does not necessarily mean that infectious virus is actively being produced. Likewise, detecting a viral RNA molecule does not automatically establish the complete biological state of the infected cell.
The strongest experimental studies therefore use multiple measurements to characterize latency.
Why Measuring the Reservoir Matters
The concept of a viral reservoir is particularly important for future HSV treatment research.
Current antiviral medicines can reduce the duration and severity of herpes symptoms and can reduce recurrences. Suppressive therapy can also reduce the risk of HSV-2 transmission in certain circumstances. However, existing treatments do not eliminate latent HSV from the body.
If scientists eventually develop treatments specifically designed to target latent HSV, they will need reliable ways to determine whether those treatments are actually reducing the latent reservoir.
Without accurate measurement, it would be difficult to distinguish between a treatment that temporarily suppresses viral activity and one that genuinely affects latent infection.
This is why better measurement technology could become an important part of future clinical trials.
NIH Identifies Latency as a Major Research Priority
The U.S. National Institutes of Health has identified HSV latency and reactivation as important areas for continued research.
The NIH Strategic Plan for HSV Research calls for greater understanding of the biological mechanisms underlying HSV latency and reactivation, as well as improved models for studying viral infection and potential treatments.
The strategy also recognizes the importance of understanding how HSV travels through the nervous system and establishes lifelong infection.
These priorities show that researchers are looking beyond outbreak management and investigating the fundamental biology that allows HSV to persist.
Could Latent HSV Eventually Be Measured in Patients?
Scientists are working toward better ways to measure latent infection, but a reliable clinical test that measures the complete latent HSV reservoir does not currently exist.
Future technologies may potentially combine genomic sequencing, molecular biomarkers, single-cell analysis, and improved human neuron models.
However, these approaches remain areas of research.
A laboratory method that detects or measures HSV under controlled experimental conditions should not be marketed as a test that can determine the amount of herpes virus inside a person’s body.
This distinction is especially important for people searching online for information about herpes cures or advanced testing.
What Does This Research Mean for People With Herpes?
For people living with HSV, the research provides a reason for cautious optimism.
Scientists are gaining more detailed knowledge about how HSV establishes latency, remains inside neurons, and reactivates.
At the same time, these discoveries do not currently change the fact that HSV is a lifelong infection for which there is no approved cure.
WHO states that herpes is treatable but not curable. Antiviral medicines can reduce symptoms and recurrences, while preventive measures can reduce transmission risk.
People living with herpes should therefore continue to rely on qualified healthcare professionals for diagnosis, treatment, and transmission-prevention guidance rather than experimental claims found online.
The Future of Latent Herpes Research
The science surrounding HSV latency is becoming increasingly sophisticated.
Human neuron models are allowing researchers to study latency in cells that more closely represent human biology. Molecular techniques are providing new information about viral genes and proteins. Single-cell technologies may eventually reveal differences between individual infected neurons.
Together, these developments could help scientists answer questions that have remained difficult for decades.
The long-term objective is not simply to detect HSV. Researchers want to understand its latent state well enough to measure it, manipulate it, and eventually develop treatments capable of controlling or eliminating the latent infection.
That remains a research goal rather than an established medical reality.
Frequently Asked Questions
Can a blood test measure latent herpes?
No. HSV antibody testing can provide evidence of previous infection, but it does not measure the total amount of latent virus stored in sensory neurons.
Where does HSV remain latent?
HSV establishes latency primarily in sensory neurons within peripheral nerve ganglia. From these locations, the virus can later reactivate and travel back toward the skin or mucosal surface.
Can current antiviral medicines eliminate latent HSV?
No. Current antiviral medicines can control symptoms and reduce recurrences but do not eliminate latent HSV.
Is there currently a herpes cure?
There is currently no approved treatment that eliminates latent HSV from the body. Researchers continue to investigate new approaches targeting latency and reactivation.
Are scientists developing better ways to study herpes latency?
Yes. Recent research using human stem-cell-derived sensory neurons provides scientists with new laboratory models for studying HSV-1 latency and reactivation.
Medical Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
